NDC 60793-602-02 - BICILLIN C-R 900/300
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 60793-602
- Requested NDC
- 60793-602-02
- Package NDCs from labels
- 60793-602-02, 60793-602-10
- Manufacturer
- Pfizer Laboratories Div Pfizer Inc | King Pharmaceuticals LLC
- Effective date
- 2026-07-21
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| PENICILLIN G - Pfizer Laboratories Div Pfizer Inc | King Pharmaceuticals LLC | Pfizer Laboratories Div Pfizer Inc | King Pharmaceuticals LLC | 2026-07-21 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 60793-602-02 | BICILLIN C-R 900/300 | 2 mL in 1 SYRINGE | INJECTION, SUSPENSION | 2 | 31 | |
| 60793-602-10 | BICILLIN C-R 900/300 | 10 in 1 PACKAGE | INJECTION, SUSPENSION | 10 | 31 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 60793-602 | BICILLIN C-R 900/300 (PENICILLIN G BENZATHINE AND PENICILLIN G PROCAINE) INJECTION, SUSPENSION [PFIZER LABORATORIES DIV PFIZER INC] | 31 | Current NDC, Legacy NDC, 2 package rows | 20240606_ba7b9199-4710-4189-a85d-77ed75befe4d.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 60793-602-02 | ML - Milliliter | 60793-602 | b817c2e5-42cd-4af7-bddd-9f8bbf1e3147 | 1 | 2014-11-05 |
| 60793-602-10 | ML - Milliliter | 60793-602 | 5bf2c7fa-3de4-483e-9817-817cfb3f6719 | 1 | 2012-07-24 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| PENICILLIN G BENZATHINE | ACTIVE INGREDIENT | RIT82F58GK | BICILLIN C-R 900/300 (PENICILLIN G BENZATHINE AND PENICILLIN G PROCAINE) INJECTION, SUSPENSION [PFIZER LABORATORIES DIV PFIZER INC] | 13 | |
| PENICILLIN G PROCAINE | ACTIVE INGREDIENT | 17R794ESYN | BICILLIN C-R 900/300 (PENICILLIN G BENZATHINE AND PENICILLIN G PROCAINE) INJECTION, SUSPENSION [PFIZER LABORATORIES DIV PFIZER INC] | 13 | |
| PENICILLIN G | ACTIVE MOIETY | Q42T66VG0C | BICILLIN C-R 900/300 (PENICILLIN G BENZATHINE AND PENICILLIN G PROCAINE) INJECTION, SUSPENSION [PFIZER LABORATORIES DIV PFIZER INC] | 13 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| BICILLIN C-R 900/300 | PENICILLIN G BENZATHINE AND PENICILLIN G PROCAINE | Pfizer Laboratories Div Pfizer Inc | ba7b9199-4710-4189-a85d-77ed75befe4d | 2026-07-21 | Boxed warning, Warnings, Adverse reactions | NDA050138 60793-602-10 60793-602-02 60793-602 60793060202 836306 836307 18e5ae26-c3f5-4d22-8657-fd767cadc25f ba7b9199-4710-4189-a85d-77ed75befe4d 17R794ESYN RIT82F58GK |
| BICILLIN L-A | PENICILLIN G BENZATHINE | Pfizer Laboratories Div Pfizer Inc | 012d46f1-d0a0-4676-a879-cd320297ab16 | 2026-07-21 | Boxed warning, Warnings, Adverse reactions | RIT82F58GK |
| BICILLIN CR | PENICILLIN G BENZATHINE AND PENICILLIN G PROCAINE | Pfizer Laboratories Div Pfizer Inc | b5640fc6-76d8-428d-80e6-760d769af8bb | 2026-07-21 | Boxed warning, Warnings, Adverse reactions | NDA050138 17R794ESYN RIT82F58GK |
| Lentocilin | PENICILLIN G BENZATHIN | LABORATRIOS ATRAL, S.A. | 1a4e5124-618b-ce44-e063-6394a90a43e3 | 2024-06-07 | Warnings, Adverse reactions | RIT82F58GK |
| BICILLIN L-A | PENICILLIN G BENZATHINE | A-S Medication Solutions | a519a9bf-8fec-4fd3-b0b2-f4ae8c7f20ce | 2023-10-24 | Boxed warning, Warnings, Adverse reactions | RIT82F58GK |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.